PF-04691502
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
PF-04691502是高效选择性PI3K/mTOR (FRAP)双重抑制剂,抑制Akt T308 (IC50 = 7.5 nM)和Akt S473 (IC50 = 3.8 nM)的磷酸化[1]。
PI3Ks是参与细胞功能的酶家族,如细胞生长、增殖、分化、运动、存活和胞内运输,从而也参与癌症。PI3Ks的功能大多与1类PI3K 在PI3K/AKT/mTOR通路中激活蛋白激酶B (PKB,亦称Akt)相关,此信号通路与细胞静止、增殖、癌症和永生直接相关。此通路中有诸多有价值的抗癌药物治疗靶点。p110δ和p110γ亚型调节免疫应答的不同方面[2]。
PF-04691502是一种有潜能的药物,由荧光偏振激酶试验、细胞、小鼠和其他动物试验得出PF-04691502的功能为抑制PI3K/AKT/mTOR通路中的1类PI3K和mTOR,此外,由此抑制作用,PF-04691502能抑制肿瘤[3, 4]。PF-04691502短时间处理能显著抑制PI3K,而对mTOR的抑制作用需要持续24-48小时。PF-04691502诱导细胞周期G1期停滞,伴随p27 Kip1的上调和Rb的下调[5]。PF-04691502的抗肿瘤活性已在U87 (PTEN null)、SKOV3 (PIK3CA 突变)、耐gefitinib和erlotinib的非小细胞肺癌异种移植物中观察到。PF-04691502在第七天抑制肿瘤生长达到72%。FDG-PET成像表明PF-04691502显著降低葡萄糖代谢。PF-04691502处理也能显著抑制PI3K/mTOR通路活性的组织标志物p-AKT (S473)和p-RPS6 (S240/244)[6]。
参考文献:
1. Yuan J."PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity". Mol Cancer Ther, 2011, 10(11), 2189-2199.
2. Okkenhaug K. "Signaling by the Phosphoinositide 3-kinase Family in Immune Cells.".Annu. Rev. Immunol, 2013. 17 (2): 675–699.
3. Maira, Sauveur-Michel; Stauffer, Frédéric; Schnell, Christian; García-Echeverría, Carlos. "PI3K inhibitors for cancer treatment: where do we stand". Biochemical Society Transactions., 2009. 37 (Pt 1): 265–72.
4. Kinross KM. "In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D; Pten Deletion Mouse Model of Ovarian Cancer". Mol Cancer Ther, 2011, 10(8), 1440-1449.
5. Yuan J, Mol Cancer Ther, 2011, 10(11), 2189-2199
6. Kinross KM, Mol Cancer Ther, 2011, 10(8), 1440-1449
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 425.48 |
Cas No. | 1013101-36-4 |
Formula | C22H27N5O4 |
Solubility | insoluble in H2O; insoluble in EtOH; ≥10.63 mg/mL in DMSO with gentle warming |
Chemical Name | 2-amino-8-[4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7-one |
SDF | Download SDF |
Canonical SMILES | CC1=C2C=C(C(=O)N(C2=NC(=N1)N)C3CCC(CC3)OCCO)C4=CN=C(C=C4)OC |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Description | PF-04691502是PI3K(α/β/δ/γ)/mTOR的ATP竞争性双重抑制剂,其Ki值分别为1.8 nM/2.1 nM/1.6 nM/1.9 nM和16 nM。 | |||||
靶点 | PI3Kδ | PI3Kα | PI3Kγ | PI3Kβ | P-Akt (S473) | mTOR |
IC50 | 1.6 nM(Ki) | 1.8 nM(Ki) | 1.9 nM(Ki) | 2.1 nM(Ki) | 3.8 nM | 16 nM |
质量控制和MSDS
- 批次: